Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xoma Royalty Corporation (XOMA)

Xoma Royalty Corporation (XOMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 303,012
  • Shares Outstanding, K 12,383
  • Annual Sales, $ 28,490 K
  • Annual Income, $ -13,820 K
  • EBIT $ 4 M
  • EBITDA $ 4 M
  • 60-Month Beta 0.86
  • Price/Sales 31.92
  • Price/Cash Flow N/A
  • Price/Book 3.30

Options Overview Details

View History
  • Implied Volatility 129.56% (+3.89%)
  • Historical Volatility 67.19%
  • IV Percentile 92%
  • IV Rank 66.95%
  • IV High 172.07% on 12/12/25
  • IV Low 43.42% on 08/18/25
  • Expected Move (DTE 1) 2.04 (8.38%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 6
  • Volume Avg (30-Day) 41
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 1,295
  • Open Int (30-Day) 1,208
  • Expected Range 22.31 to 26.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.12
  • Number of Estimates 3
  • High Estimate 0.05
  • Low Estimate -0.29
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +73.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.29 +9.24%
on 02/11/26
28.60 -14.86%
on 01/22/26
-2.02 (-7.66%)
since 01/16/26
3-Month
22.29 +9.24%
on 02/11/26
34.79 -30.01%
on 12/10/25
-8.44 (-25.74%)
since 11/18/25
52-Week
18.35 +32.68%
on 04/07/25
39.92 -39.00%
on 10/03/25
-0.78 (-3.10%)
since 02/18/25

Most Recent Stories

More News
XOMA Royalty to Present at Investor Conferences in March

EMERYVILLE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following...

XOMA : 24.35 (-0.49%)
XOMAP : 26.24 (+0.46%)
XOMAO : 25.37 (+0.04%)
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.

EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role...

GBIO : 5.34 (-6.97%)
XOMA : 24.35 (-0.49%)
XOMAP : 26.24 (+0.46%)
XOMAO : 25.37 (+0.04%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...

XOMA : 24.35 (-0.49%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...

XOMA : 24.35 (-0.49%)
XOMA Royalty Announces CFO Transition

EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from...

XOMA : 24.35 (-0.49%)
XOMAP : 26.24 (+0.46%)
XOMAO : 25.37 (+0.04%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...

XOMA : 24.35 (-0.49%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...

XOMA : 24.35 (-0.49%)
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

– Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) – – XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with...

XOMA : 24.35 (-0.49%)
XOMAP : 26.24 (+0.46%)
XOMAO : 25.37 (+0.04%)
XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash...

XOMA : 24.35 (-0.49%)
XOMAP : 26.24 (+0.46%)
XOMAO : 25.37 (+0.04%)
XOMA Royalty Enters into Agreement to Acquire Generation Bio

- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP)...

GBIO : 5.34 (-6.97%)
XOMA : 24.35 (-0.49%)

Business Summary

XOMA ROYALTY is a biotechnology royalty aggregator. The company acquires the potential future economics associated with pre-commercial therapeutic candidates which have been licensed to pharmaceutical or biotechnology companies. XOMA ROYALTY, formerly known as XOMA Corporation, is based in EMERYVILLE,...

See More

Key Turning Points

3rd Resistance Point 25.61
2nd Resistance Point 25.34
1st Resistance Point 24.85
Last Price 24.35
1st Support Level 24.09
2nd Support Level 23.82
3rd Support Level 23.33

See More

52-Week High 39.92
Fibonacci 61.8% 31.68
Fibonacci 50% 29.14
Fibonacci 38.2% 26.59
Last Price 24.35
52-Week Low 18.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar